NASDAQ:CLBS Caladrius Biosciences (CLBS) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free CLBS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.43▼$8.3852-Week Range N/AVolume466,373 shsAverage Volume522,308 shsMarket Capitalization$26.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Caladrius Biosciences alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Caladrius Biosciences Stock (NASDAQ:CLBS)Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Read More Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert CLBS Stock News HeadlinesDecember 1, 2022 | finance.yahoo.comHARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATIONSeptember 16, 2022 | finanznachrichten.deCaladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionSeptember 15, 2022 | finanznachrichten.deCaladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 15, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 14, 2022 | seekingalpha.comCLBS Caladrius Biosciences, Inc.September 14, 2022 | finance.yahoo.comCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 8, 2022 | msn.comHow to get the Protea Caladrius collection in Warframe: VeilbreakerMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…September 8, 2022 | finance.yahoo.comCaladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022August 10, 2022 | finance.yahoo.comCaladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic CancerAugust 5, 2022 | seekingalpha.comCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comCaladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 4, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANTAugust 3, 2022 | msn.comEarnings Outlook For Caladrius BiosciencesAugust 2, 2022 | finance.yahoo.comCaladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseJuly 28, 2022 | finance.yahoo.comCaladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimeJuly 6, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and HepatologyJune 9, 2022 | finance.yahoo.comCaladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials GroupJune 8, 2022 | finance.yahoo.comCaladrius Biosciences to Present at the BIO International Convention 2022May 26, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual MeetingMay 24, 2022 | finance.yahoo.comCaladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease StudyMay 23, 2022 | finance.yahoo.comCaladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular DysfunctionMay 19, 2022 | finance.yahoo.comCaladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney DiseaseMay 18, 2022 | finance.yahoo.comCaladrius Biosciences to Present at the H.C. Wainwright Global Investment ConferenceMay 6, 2022 | benzinga.comCALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBSMay 6, 2022 | seekingalpha.comCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call TranscriptSee More Headlines Receive CLBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNASDAQ:CLBS CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees27Year Founded2006Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.24% Return on Assets-26.08% Debt Debt-to-Equity RatioN/A Current Ratio22.33 Quick Ratio22.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares60,583,000Free Float59,250,000Market Cap$26.05 million OptionableOptionable Beta0.91 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. David J. Mazzo B.A. (Hons) (Age 65)B.Sc. (Hons.), M.Sc., Ph.D., Pres, CEO & Director Comp: $957.69kDr. Kristen K. Buck M.D. (Age 48)Exec. VP of R&D and Chief Medical Officer Comp: $825kMr. James NiscoVP of Fin. & TreasuryMr. Gregory S. BerkinChief Information OfficerMr. John D. MendittoVP of Investor Relations & Corp. CommunicationsEric PowersDirector of Communications and MarketingMs. Gail Holler (Age 63)VP of HR Dr. Ian Zhang Ph.D. (Age 57)MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc Dr. William K. Sietsema Ph.D. (Age 66)VP of Global Regulatory Affairs More ExecutivesKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSELisata TherapeuticsNASDAQ:LSTAMEI PharmaNASDAQ:MEIPExagenNASDAQ:XGNLipocineNASDAQ:LPCNView All Competitors CLBS Stock Analysis - Frequently Asked Questions How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences, Inc. (NASDAQ:CLBS) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share for the quarter, topping the consensus estimate of ($1.95) by $0.15. During the same period in the previous year, the company earned ($4.35) earnings per share. When did Caladrius Biosciences' stock split? Caladrius Biosciences shares reverse split on Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO? 1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend. What other stocks do shareholders of Caladrius Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Caladrius Biosciences investors own include Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Karyopharm Therapeutics (KPTI), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX) and CTI BioPharma (CTIC). This page (NASDAQ:CLBS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caladrius Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.